Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).
Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.Peer-Reviewed Original ResearchPrescription drug coverageAnorexia/cachexia syndromeDrug coveragePocket costsRisk/benefit ratioPatient-clinician discussionsSupportive care guidelinesFinancial burdenList of drugsCost of drugsUse of drugsHigh financial burdenEnd of lifeCachexia syndromeCare guidelinesUnwanted side effectsGeneric olanzapineSide effectsClinical practiceCertain drugsMultiple drugsStudy authorsBenefit ratioDrugsLimited benefit